Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

DSpace Repository

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

Author: Schneeweiss, Andreas; Ettl, Johannes; Lueftner, Diana; Beckmann, Matthias W.; Belleville, Erik; Fasching, Peter A.; Fehm, Tanja N.; Geberth, Matthias; Haberle, Lothar; Hadji, Peyman; Hartkopf, Andreas D.; Hielscher, Carsten; Huober, Jens; Ruckhaberle, Eugen; Janni, Wolfgang; Kolberg, Hans Christian; Kurbacher, Christian M.; Klein, Evelyn; Lux, Michael P.; Mueller, Volkmar; Nabieva, Naiba; Overkamp, Friedrich; Tesch, Hans; Laakmann, Elena; Taran, Florin-Andrei; Seitz, Julia; Thomssen, Christoph; Untch, Michael; Wimberger, Pauline; Wuerstlein, Rachel; Volz, Bernhard; Wallwiener, Diethelm; Wallwiener, Markus; Brucker, Sara Y.
Tübinger Autor(en):
Hartkopf, Andreas
Ţăran, Florin-Andrei
Wallwiener, Diethelm
Brucker, Sara
Published in: Breast (2020), Bd. 54, S. 88-95
Verlagsangabe: Churchill Livingstone
Language: English
Full text: http://dx.doi.org/10.1016/j.breast.2020.08.011
ISSN: 1532-3080
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)